Sequential intravenous allogeneic mesenchymal stromal cells as a potential treatment for thromboangiitis obliterans (Buerger’s disease)

Autor: Fermín Sánchez-Guijo, Jorge Diego Martin-Rufino, Alba Redondo, Raquel Rueda, Francisco S. Lozano, Rafael Fernandez-Samos, Eva Villarón
Jazyk: angličtina
Rok vydání: 2018
Předmět:
0301 basic medicine
Oncology
Adult
Male
medicine.medical_specialty
medicine.medical_treatment
Short Report
Medicine (miscellaneous)
Inflammation
Disease
030204 cardiovascular system & hematology
Mesenchymal Stem Cell Transplantation
Biochemistry
Genetics and Molecular Biology (miscellaneous)
lcsh:Biochemistry
03 medical and health sciences
0302 clinical medicine
Immune system
Internal medicine
Thromboangiitis obliterans
medicine
Humans
Transplantation
Homologous
lcsh:QD415-436
Buerger's disease
lcsh:R5-920
business.industry
Mesenchymal stem cell
Mesenchymal Stem Cells
Cell Biology
medicine.disease
030104 developmental biology
Treatment Outcome
Amputation
Molecular Medicine
Administration
Intravenous
medicine.symptom
Stem cell
Cell transplantation
business
Vasculitis
lcsh:Medicine (General)
Allogeneic mesenchymal stromal cells
Zdroj: Stem Cell Research & Therapy
Stem Cell Research & Therapy, Vol 9, Iss 1, Pp 1-6 (2018)
ISSN: 1757-6512
Popis: Thromboangiitis obliterans (TAO), also known as Buerger’s Disease, is an occlusive vasculitis linked with high morbidity and amputation risk. To date, TAO is deemed incurable due to the lack of a definitive treatment. The immune system and inflammation are proposed to play a central role in TAO pathogenesis. Due to their immunomodulatory effects, mesenchymal stromal cells (MSCs) are the subject of intense research for the treatment of a wide range of immune-mediated diseases. Thus far, local intramuscular injections of autologous or allogeneic MSCs have shown promising results in TAO. However, sequential intravenous allogeneic MSC administration has not yet been explored, which we hypothesized could exert a systemic anti-inflammatory effect in the vasculature and modulate the immune response. Here, we report the first case of a TAO patient at amputation risk treated with four sequential intravenous infusions of bone marrow-derived allogeneic MSCs from a healthy donor. Following administration, there was significant regression of foot skin ulcers and improvements in rest pain, Walking Impairment Questionnaire scores, and quality of life. Sixteen months after the infusion, the patient had not required any further amputations. This report highlights the potential of sequential allogeneic MSC infusions as an effective treatment for TAO, warranting further studies to compare this approach with the more conventionally used intramuscular MSC administration and other cell-based therapies.
Databáze: OpenAIRE
Externí odkaz: